Table 3.

Summary of adverse events in safety population

Group	Oxygen group (n = 54)	Hydrogen/oxygen group (n = 54)
Number of patients, n (%)
Any adverse events	42 (77.8%)	34 (63.0%)
Main AEs
Hypokalemia	3 (5.6%)	2 (3.7%)
Abnormal liver function	3 (5.6%)	1 (1.9%)
Upper respiratory infection	3 (5.6%)	3 (5.6%)
Elevated C-reactive protein	2 (3.7%)	4 (7.4%)
Elevated blood pressure	2 (3.7%)	2 (3.7%)
Cough	2 (3.7%)	2 (3.7%)
Phlegm-retention	3 (5.6%)	0 (0.0%)
Wheezing	4 (7.4%)	0 (0.0%)
Agrypnia	2 (3.7%)	2 (3.7%)
Any severe adverse events	7 (13.0%)	2 (3.7%)
Abnormal liver function	1 (1.9%)	0 (0.0%)
Infection (lung, upper respiratory)	3 (5.6%)	0 (0.0%)
Bacterial infection	1 (1.9%)	0 (0.0%)
Pulmonary inflammation	0 (0.0%)	1 (1.9%)
Wheezing	2 (3.7%)	0 (0.0%)
Ileus	0 (0.0%)	1 (1.9%)
Any device-related adverse events	3 (5.6%)	2 (3.7%)
Any adverse events leading to withdrawal	2 (3.7%)	2 (3.7%)
Number of events, n
Any adverse events	82	63
An severe adverse event	7	2
Any device-related adverse events	3	3
Upper respiratory tract infection	31(14.69)	26(20.31)